Longeveron Inc (LGVN)

$0.75 -0.09 (-10.49%)
Market Cap 19.50M
Revenue (ttm) 1.20M
Net Income (ttm) -22.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,891.67%
Debt to Equity Ratio 0.03
Volume 571,600
Avg Vol 6,818,294
Day's Range N/A - N/A
Shares Out 23.27M
Stochastic %K 0%
Beta -0.31
Analysts Strong Sell
Price Target $6.11

Company Profile

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 470 2550
Address:
Life Science & Technology Park, Suite 520 1951 NW 7th Avenue, Miami, United States
only1mc
only1mc May. 12 at 11:23 PM
$WOK could we be witnessing another $LGVN. 3$- 45$ in 48 hours🤔
2 · Reply
Threepence
Threepence May. 12 at 10:23 PM
$LGVN https://investors.longeveron.com/news/News/news-details/2026/Longeveron-Announces-Independent-Data-Monitoring-Committee-Positive-Review-and-Recommendation-to-Complete-Phase-2b-Stem-Cell-Therapy-Clinical-Trial-in-Hypoplastic-Left-Heart-Syndrome-HLHS/default.aspx It aint over until it’s over, and this is very far from over. Why are people so quick to panic with every bump in the road and then complain about volatility and shorts? Have faith and hold long, that’s the only way to win here.
0 · Reply
Huskersnsaints
Huskersnsaints May. 12 at 3:32 PM
$LGVN WONDER MAJOR BIG PHARMA DROPPED THE CASH!!!! Always follow the money!!!!!
2 · Reply
Huskersnsaints
Huskersnsaints May. 12 at 1:48 PM
$LGVN of course the upgrades basically did nothing but and down grade and watch the bottom fall out CRIMINALS ALWAYS WIN!!!!
1 · Reply
Lstreak
Lstreak May. 11 at 2:05 PM
$LGVN Have a feeling this will be touching on 52 week lows again!!
0 · Reply
Stock_Catcher
Stock_Catcher May. 11 at 1:10 PM
$LGVN Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
0 · Reply
OpenOutcrier
OpenOutcrier May. 11 at 12:18 PM
$LGVN (-1.2% pre) LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design https://ooc.bz/l/101726
0 · Reply
Schmidt97
Schmidt97 May. 11 at 7:43 AM
$LGVN I wouldn’t be surprised if this goes back to $0.50. It’s a shame because this had so much momentum. We still have 3 drugs in production. 1 minor set back shouldn’t always be such a downfall
0 · Reply
mikesterz7
mikesterz7 May. 9 at 1:17 AM
$LGVN The agency explicitly stated that the trial’s current primary endpoint is “not an appropriate endpoint to demonstrate efficacy.”
1 · Reply
StocktwitsNews
StocktwitsNews May. 9 at 12:05 AM
LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design $LGVN $VTI $VXF https://stocktwits.com/news/equity/markets/lgvn-stock-slips-after-hours-as-fda-flags-concerns-on-rare-heart-defect-trial-design/cZX3e1VRegp
0 · Reply
Latest News on LGVN
Longeveron reports DMC approval for laromestrocel study to continue as designed

2026-05-11T20:09:41.000Z - 1 day ago

Longeveron reports DMC approval for laromestrocel study to continue as designed

Longeveron downgraded to Hold from Buy at Maxim

2026-05-11T15:43:29.000Z - 1 day ago

Longeveron downgraded to Hold from Buy at Maxim

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

May 11, 2026, 9:10 AM EDT - 1 day ago

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

Longeveron provides update on laromestrocel development after Type C meeting

2026-05-08T22:59:18.000Z - 4 days ago

Longeveron provides update on laromestrocel development after Type C meeting

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

May 8, 2026, 4:05 PM EDT - 4 days ago

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026

May 5, 2026, 4:15 PM EDT - 7 days ago

Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026

Longeveron price target lowered to $8 from $10 at H.C. Wainwright

2026-05-04T10:15:51.000Z - 9 days ago

Longeveron price target lowered to $8 from $10 at H.C. Wainwright

Longeveron files to sell 30.87M shares of Class A common stock for holders

2026-04-10T20:05:14.000Z - 4 weeks ago

Longeveron files to sell 30.87M shares of Class A common stock for holders

Longeveron granted Chinese patent for potency assay methods

2026-04-08T13:38:32.000Z - 4 weeks ago

Longeveron granted Chinese patent for potency assay methods

Longeveron granted Chinese patent for potency assay methods

2026-04-08T13:27:11.000Z - 4 weeks ago

Longeveron granted Chinese patent for potency assay methods

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Apr 8, 2026, 9:15 AM EDT - 4 weeks ago

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Longeveron price target lowered to $2 from $3 at Roth Capital

2026-03-18T23:20:16.000Z - 7 weeks ago

Longeveron price target lowered to $2 from $3 at Roth Capital

Longeveron Earnings Call Transcript: Q4 2025

Mar 17, 2026, 4:30 PM EDT - 2 months ago

Longeveron Earnings Call Transcript: Q4 2025

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

Mar 17, 2026, 4:05 PM EDT - 2 months ago

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

Longeveron Announces Closing of Private Placement of up to $30 Million

Mar 11, 2026, 4:05 PM EDT - 2 months ago

Longeveron Announces Closing of Private Placement of up to $30 Million

3 Penny Stocks to Watch Now, 3/11/26

2026-03-11T14:11:00.000Z - 2 months ago

3 Penny Stocks to Watch Now, 3/11/26

ATPC INKT

Longeveron prices 6.01M shares at 52c in private placement

2026-03-10T13:16:09.000Z - 2 months ago

Longeveron prices 6.01M shares at 52c in private placement

Longeveron: Phase 2b results show laromestrocel improved physical condition

2026-02-25T16:10:58.000Z - 2 months ago

Longeveron: Phase 2b results show laromestrocel improved physical condition

Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell

Feb 25, 2026, 11:05 AM EST - 2 months ago

Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell

Longeveron names Stephen Willard as CEO, succeeding Than Powell

2026-02-13T21:35:23.000Z - 3 months ago

Longeveron names Stephen Willard as CEO, succeeding Than Powell

Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

Feb 13, 2026, 4:30 PM EST - 3 months ago

Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

Longeveron ‘applauds’ Mikaela Naylon Give Kids a Chance Act passage

2026-02-05T14:21:01.000Z - 3 months ago

Longeveron ‘applauds’ Mikaela Naylon Give Kids a Chance Act passage

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program

Feb 5, 2026, 9:15 AM EST - 3 months ago

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program

Longeveron granted Japan patent for potency assay methods for MSCs

2026-01-29T14:21:08.000Z - 3 months ago

Longeveron granted Japan patent for potency assay methods for MSCs

Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Jan 29, 2026, 9:15 AM EST - 3 months ago

Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Longeveron granted FDA Type C Meeting ahead of ELPIS II data readout

2026-01-26T14:21:24.000Z - 3 months ago

Longeveron granted FDA Type C Meeting ahead of ELPIS II data readout

Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026

Dec 29, 2025, 9:15 AM EST - 4 months ago

Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026

Longeveron granted U.S. patent for method of treating female sexual dysfunction

2025-12-17T14:20:32.000Z - 5 months ago

Longeveron granted U.S. patent for method of treating female sexual dysfunction

Longeveron granted Canadian patent covering laromestrocel administration

2025-12-02T14:25:12.000Z - 5 months ago

Longeveron granted Canadian patent covering laromestrocel administration

Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

Dec 2, 2025, 9:15 AM EST - 5 months ago

Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

Longeveron to present MRI biomarker data in Alzheimer’s at CTAD 2025

2025-12-01T17:10:18.000Z - 5 months ago

Longeveron to present MRI biomarker data in Alzheimer’s at CTAD 2025

Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Dec 1, 2025, 12:00 PM EST - 5 months ago

Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Nov 19, 2025, 9:15 AM EST - 6 months ago

Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Longeveron granted U.S. patent for administration of MSCs

2025-11-12T14:11:30.000Z - 6 months ago

Longeveron granted U.S. patent for administration of MSCs

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

Nov 12, 2025, 9:05 AM EST - 6 months ago

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

Longeveron reports Q3 EPS (39c), consensus (26c)

2025-11-04T21:45:31.000Z - 6 months ago

Longeveron reports Q3 EPS (39c), consensus (26c)

Longeveron Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 6 months ago

Longeveron Earnings Call Transcript: Q3 2025

Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

Oct 27, 2025, 9:15 AM EDT - 7 months ago

Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Oct 6, 2025, 9:15 AM EDT - 7 months ago

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Sep 22, 2025, 9:15 AM EDT - 8 months ago

Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Longeveron® Announces Key Leadership Updates

Sep 3, 2025, 4:05 PM EDT - 8 months ago

Longeveron® Announces Key Leadership Updates

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 9:15 AM EDT - 9 months ago

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Longeveron Earnings Call Transcript: Q2 2025

Aug 13, 2025, 4:30 PM EDT - 9 months ago

Longeveron Earnings Call Transcript: Q2 2025

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 13, 2025, 4:05 PM EDT - 9 months ago

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Aug 11, 2025, 4:15 PM EDT - 9 months ago

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Longeveron Announces Up To $17.5 Million Public Offering

Aug 8, 2025, 1:28 PM EDT - 9 months ago

Longeveron Announces Up To $17.5 Million Public Offering

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

Aug 5, 2025, 9:15 AM EDT - 10 months ago

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Jul 21, 2025, 9:15 AM EDT - 10 months ago

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Jul 8, 2025, 9:15 AM EDT - 11 months ago

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Longeveron® Appoints Than Powell as Chief Business Officer

Jun 26, 2025, 9:05 AM EDT - 11 months ago

Longeveron® Appoints Than Powell as Chief Business Officer

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Jun 24, 2025, 6:30 AM EDT - 11 months ago

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron Transcript: AGM 2025

Jun 13, 2025, 1:00 PM EDT - 11 months ago

Longeveron Transcript: AGM 2025

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 9, 2025, 9:15 AM EDT - 1 year ago

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Longeveron® to Attend BIO International Convention 2025

May 20, 2025, 9:15 AM EDT - 1 year ago

Longeveron® to Attend BIO International Convention 2025

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

May 12, 2025, 7:15 AM EDT - 1 year ago

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

Longeveron Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Longeveron Earnings Call Transcript: Q1 2025

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 1 year ago

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

May 2, 2025, 8:30 AM EDT - 1 year ago

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Longeveron Transcript: 37th Annual ROTH Conference

Mar 18, 2025, 12:00 PM EDT - 1 year ago

Longeveron Transcript: 37th Annual ROTH Conference

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

Longeveron® to Present at the 37th Annual Roth Conference

Mar 5, 2025, 9:25 AM EST - 1 year ago

Longeveron® to Present at the 37th Annual Roth Conference

Longeveron Earnings Call Transcript: Q4 2024

Feb 28, 2025, 4:30 PM EST - 1 year ago

Longeveron Earnings Call Transcript: Q4 2024

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Feb 28, 2025, 4:04 PM EST - 1 year ago

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Longeveron Transcript: Emerging Growth Conference 79

Feb 19, 2025, 3:10 PM EST - 1 year ago

Longeveron Transcript: Emerging Growth Conference 79

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Feb 18, 2025, 9:25 AM EST - 1 year ago

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Longeveron Transcript: Biotech Showcase 2025

Jan 14, 2025, 7:00 PM EST - 1 year ago

Longeveron Transcript: Biotech Showcase 2025

Longeveron to Present at Biotech Showcase 2025

Dec 18, 2024, 9:10 AM EST - 1 year ago

Longeveron to Present at Biotech Showcase 2025

Longeveron Transcript: Emerging Growth Conference77

Dec 5, 2024, 12:00 PM EST - 1 year ago

Longeveron Transcript: Emerging Growth Conference77

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Dec 2, 2024, 9:05 AM EST - 1 year ago

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Longeveron Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Longeveron Earnings Call Transcript: Q3 2024

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Nov 11, 2024, 9:05 AM EST - 1 year ago

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 29, 2024, 10:00 AM EDT - 1 year ago

Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 27, 2024, 3:10 PM EDT - 1 year ago

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 14, 2024, 9:05 AM EDT - 1 year ago

Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 9, 2024, 9:05 AM EDT - 1 year ago

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

Oct 7, 2024, 9:05 AM EDT - 1 year ago

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024, 9:05 AM EDT - 1 year ago

Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Sep 26, 2024, 9:05 AM EDT - 1 year ago

Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Longeveron Earnings Call Transcript: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Longeveron Earnings Call Transcript: Q2 2024

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

Jul 28, 2024, 4:51 PM EDT - 1 year ago

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

only1mc
only1mc May. 12 at 11:23 PM
$WOK could we be witnessing another $LGVN. 3$- 45$ in 48 hours🤔
2 · Reply
Threepence
Threepence May. 12 at 10:23 PM
$LGVN https://investors.longeveron.com/news/News/news-details/2026/Longeveron-Announces-Independent-Data-Monitoring-Committee-Positive-Review-and-Recommendation-to-Complete-Phase-2b-Stem-Cell-Therapy-Clinical-Trial-in-Hypoplastic-Left-Heart-Syndrome-HLHS/default.aspx It aint over until it’s over, and this is very far from over. Why are people so quick to panic with every bump in the road and then complain about volatility and shorts? Have faith and hold long, that’s the only way to win here.
0 · Reply
Huskersnsaints
Huskersnsaints May. 12 at 3:32 PM
$LGVN WONDER MAJOR BIG PHARMA DROPPED THE CASH!!!! Always follow the money!!!!!
2 · Reply
Huskersnsaints
Huskersnsaints May. 12 at 1:48 PM
$LGVN of course the upgrades basically did nothing but and down grade and watch the bottom fall out CRIMINALS ALWAYS WIN!!!!
1 · Reply
Lstreak
Lstreak May. 11 at 2:05 PM
$LGVN Have a feeling this will be touching on 52 week lows again!!
0 · Reply
Stock_Catcher
Stock_Catcher May. 11 at 1:10 PM
$LGVN Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
0 · Reply
OpenOutcrier
OpenOutcrier May. 11 at 12:18 PM
$LGVN (-1.2% pre) LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design https://ooc.bz/l/101726
0 · Reply
Schmidt97
Schmidt97 May. 11 at 7:43 AM
$LGVN I wouldn’t be surprised if this goes back to $0.50. It’s a shame because this had so much momentum. We still have 3 drugs in production. 1 minor set back shouldn’t always be such a downfall
0 · Reply
mikesterz7
mikesterz7 May. 9 at 1:17 AM
$LGVN The agency explicitly stated that the trial’s current primary endpoint is “not an appropriate endpoint to demonstrate efficacy.”
1 · Reply
StocktwitsNews
StocktwitsNews May. 9 at 12:05 AM
LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design $LGVN $VTI $VXF https://stocktwits.com/news/equity/markets/lgvn-stock-slips-after-hours-as-fda-flags-concerns-on-rare-heart-defect-trial-design/cZX3e1VRegp
0 · Reply
focafoca99
focafoca99 May. 8 at 8:46 PM
$LGVN briefed on FDA Type C meeting feedback for its HLHS cell therapy trial.
0 · Reply
Dorps332
Dorps332 May. 8 at 8:20 PM
$LGVN about to take my 40k loss
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor May. 8 at 8:17 PM
$LGVN FDA no longer considers their trial as pivotal. Wont accept the original primary endpoint + wont accept changing the primary mid study (after blinded interim analysis has already happened)
1 · Reply
AConsciousApe
AConsciousApe May. 8 at 8:15 PM
$LGVN
0 · Reply
niewco
niewco May. 8 at 8:12 PM
$LGVN 👀
0 · Reply
Dorps332
Dorps332 May. 8 at 8:10 PM
$LGVN trash company
0 · Reply
theSnip3r
theSnip3r May. 8 at 8:09 PM
$LGVN
0 · Reply
AlertsAndNews
AlertsAndNews May. 8 at 8:05 PM
$LGVN news just out Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
0 · Reply
topstockalerts
topstockalerts May. 7 at 1:01 AM
$LGVN not chasing but definitely paying attention here
0 · Reply
shuffle13
shuffle13 May. 6 at 11:22 PM
$ERNA $LGVN im done arguing with a 16 year old
0 · Reply
shuffle13
shuffle13 May. 6 at 11:13 PM
$ERNA love you Richard!...take a look at $LGVN AFTER IT ROCKETTED on news...i almost wish we could set up a Polymarket right now-your bet against mine...the first and MOST obvious answer is: THEY NEED CASH!...Their number right now-only represent 'operating" with NO NEW expenses...since your he bio expert...you tell me...."how do they plan to fund" the study? 😃...Maybe theyll just have people (like yourself) keep buying shares-help fund-i dont know lol...Science doesn't pay for clinical trials—cash does. A 1-for-25 reverse split on May 4 followed by 'breakthrough' mouse data on May 6 is the textbook slaughter setup to generate the volume needed for an offering. Your 'syngeneic models' don't change the fact that the company has a massive burn and just cleaned the share structure to sell into this pump. If this were about the science and not a 424B5 trap, the stock wouldn't have rejected $7.70 on 60 million shares of volume.
1 · Reply
Dorps332
Dorps332 May. 4 at 4:07 PM
$LGVN damn this is trash
0 · Reply